206 related articles for article (PubMed ID: 31299132)
1. Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long-term impairment of the GIP system.
Gabe MBN; van der Velden WJC; Gadgaard S; Smit FX; Hartmann B; Bräuner-Osborne H; Rosenkilde MM
Basic Clin Pharmacol Toxicol; 2020 Jun; 126 Suppl 6(Suppl 6):122-132. PubMed ID: 31299132
[TBL] [Abstract][Full Text] [Related]
2. A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity.
Mohammad S; Patel RT; Bruno J; Panhwar MS; Wen J; McGraw TE
Mol Cell Biol; 2014 Oct; 34(19):3618-29. PubMed ID: 25047836
[TBL] [Abstract][Full Text] [Related]
3. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
4. Human GIP(3-30)NH
Gabe MBN; Sparre-Ulrich AH; Pedersen MF; Gasbjerg LS; Inoue A; Bräuner-Osborne H; Hartmann B; Rosenkilde MM
Biochem Pharmacol; 2018 Apr; 150():97-107. PubMed ID: 29378179
[TBL] [Abstract][Full Text] [Related]
5. Internalization and desensitization of the human glucose-dependent-insulinotropic receptor is affected by N-terminal acetylation of the agonist.
Ismail S; Dubois-Vedrenne I; Laval M; Tikhonova IG; D'Angelo R; Sanchez C; Clerc P; Gherardi MJ; Gigoux V; Magnan R; Fourmy D
Mol Cell Endocrinol; 2015 Oct; 414():202-15. PubMed ID: 26225752
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
7. GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment.
Gabe MBN; Skov-Jeppesen K; Gasbjerg LS; Schiellerup SP; Martinussen C; Gadgaard S; Boer GA; Oeke J; Torz LJ; Veedfald S; Svane MS; Bojsen-Møller KN; Madsbad S; Holst JJ; Hartmann B; Rosenkilde MM
Pharmacol Res; 2022 Feb; 176():106058. PubMed ID: 34995796
[TBL] [Abstract][Full Text] [Related]
8. Insights into agonist-elicited activation of the human glucose-dependent insulinotropic polypeptide receptor.
Yuliantie E; van der Velden WJC; Labroska V; Dai A; Zhao F; Darbalaei S; Deganutti G; Xu T; Zhou Q; Yang D; Rosenkilde MM; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2021 Oct; 192():114715. PubMed ID: 34339714
[TBL] [Abstract][Full Text] [Related]
9. GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology.
Rosenkilde MM; Lindquist P; Kizilkaya HS; Gasbjerg LS
Peptides; 2024 Jul; 177():171212. PubMed ID: 38608836
[TBL] [Abstract][Full Text] [Related]
10. Role of G protein-coupled receptor kinases in glucose-dependent insulinotropic polypeptide receptor signaling.
Tseng CC; Zhang XY
Endocrinology; 2000 Mar; 141(3):947-52. PubMed ID: 10698169
[TBL] [Abstract][Full Text] [Related]
11. Characterization of genetic variants of GIPR reveals a contribution of β-arrestin to metabolic phenotypes.
Kizilkaya HS; Sørensen KV; Madsen JS; Lindquist P; Douros JD; Bork-Jensen J; Berghella A; Gerlach PA; Gasbjerg LS; Mokrosiński J; Mowery SA; Knerr PJ; Finan B; Campbell JE; D'Alessio DA; Perez-Tilve D; Faas F; Mathiasen S; Rungby J; Sørensen HT; Vaag A; Nielsen JS; Holm JC; Lauenborg J; Damm P; Pedersen O; Linneberg A; Hartmann B; Holst JJ; Hansen T; Wright SC; Lauschke VM; Grarup N; Hauser AS; Rosenkilde MM
Nat Metab; 2024 Jun; ():. PubMed ID: 38871982
[TBL] [Abstract][Full Text] [Related]
12. Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand.
Yaqub T; Tikhonova IG; Lättig J; Magnan R; Laval M; Escrieut C; Boulègue C; Hewage C; Fourmy D
Mol Pharmacol; 2010 Apr; 77(4):547-58. PubMed ID: 20061446
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a rare glucose-dependent insulinotropic polypeptide receptor variant in a patient with diabetes.
Jacobi SF; Khajavi N; Kleinau G; Teumer A; Scheerer P; Homuth G; Völzke H; Wiegand S; Kühnen P; Krude H; Gong M; Raile K; Biebermann H
Diabetes Obes Metab; 2019 May; 21(5):1168-1176. PubMed ID: 30784161
[TBL] [Abstract][Full Text] [Related]
14. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice.
Harada N; Yamada Y; Tsukiyama K; Yamada C; Nakamura Y; Mukai E; Hamasaki A; Liu X; Toyoda K; Seino Y; Inagaki N
Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E61-8. PubMed ID: 17971513
[TBL] [Abstract][Full Text] [Related]
15. Mapping interactions of gastric inhibitory polypeptide with GIPR N-terminus using NMR and molecular dynamics simulations.
Tikhele SH; Pissurlenkar RR; Srivastava S; Saran A; Coutinho EC
J Pept Sci; 2010 Aug; 16(8):383-91. PubMed ID: 20607844
[TBL] [Abstract][Full Text] [Related]
16. Spatiotemporal regulation of GIPR signaling impacts glucose homeostasis as revealed in studies of a common GIPR variant.
Yammine L; Picatoste B; Abdullah N; Leahey RA; Johnson EF; Gómez-Banoy N; Rosselot C; Wen J; Hossain T; Goncalves MD; Lo JC; Garcia-Ocaña A; McGraw TE
Mol Metab; 2023 Dec; 78():101831. PubMed ID: 37925022
[TBL] [Abstract][Full Text] [Related]
17. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor.
Ravn P; Madhurantakam C; Kunze S; Matthews E; Priest C; O'Brien S; Collinson A; Papworth M; Fritsch-Fredin M; Jermutus L; Benthem L; Gruetter M; Jackson RH
J Biol Chem; 2013 Jul; 288(27):19760-72. PubMed ID: 23689510
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of a GPCR by β-Arrestin2-Mediated Switch from an Endosomal to a TGN Recycling Pathway.
Abdullah N; Beg M; Soares D; Dittman JS; McGraw TE
Cell Rep; 2016 Dec; 17(11):2966-2978. PubMed ID: 27974210
[TBL] [Abstract][Full Text] [Related]
19. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
Gasbjerg LS; Gabe MBN; Hartmann B; Christensen MB; Knop FK; Holst JJ; Rosenkilde MM
Peptides; 2018 Feb; 100():173-181. PubMed ID: 29412817
[TBL] [Abstract][Full Text] [Related]
20. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
